about
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host diseaseMelanoma: clinical features and genomic insights.Non-infectious granulomatous diseases of the skin and their associated systemic diseases: an evidence-based update to important clinical questions.BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.Pediatric melanoma, moles, and sun safety.Voriconazole phototoxicity in children: a retrospective review.Multidisciplinary interventions in the management of atopic dermatitis.Treatment of postsurgical pyoderma gangrenosum with a high-potency topical steroid.Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center.Delayed-type hypersensitivity to vaccine aluminum adjuvant causing subcutaneous leg mass and urticaria in a child.Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation.Non-malignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children.Evolving Childhood Melanoma Monitored by Parental Photodocumentation.Enlargement of eccrine angiomatous hamartoma following trauma.Lipofibromatosis-like neural tumor: Case report of a unique infantile presentation.Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.'Monster cell' melanoma with pulmonary metastasis and cyclin D1 amplificationClinical features and outcomes of spitzoid proliferations in children and adolescents.Lichen planopilaris: retrospective study and stepwise therapeutic approachBroad range of adverse cutaneous eruptions in patients on TNF-alpha antagonistsHistopathology of measles exanthem: a case with characteristic features and eosinophilsRefractory antilaminin γ1 pemphigoid successfully treated with intravenous immunoglobulin and mycophenolate mofetilA Randomized Controlled Trial of an Eczema Care PlanContrasting features of childhood and adolescent melanomasPigmented purpuric dermatosis: a striking but benign cutaneous entityA pediatric approach to management of skin growths in basal cell nevus syndromeComment on "Parent and child perspectives on perceived barriers to child sun protection and their association with sun protection strategies among children of melanoma survivors"Associations of Eczema Severity and Parent Knowledge With Child Quality of Life in a Pediatric Primary Care PopulationClinical spectrum of cutaneous melanoma morphologyRisk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young AdultsCorrection to: Medical Options for the Adjuvant Treatment and Management of Pediatric MelanomaSun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort StudyMedical Options for the Adjuvant Treatment and Management of Pediatric MelanomaPediatric dermatology eConsults: Reduced wait times and dermatology office visits
P50
Q24626202-664F8791-5B97-457A-A05F-48148D1C1F65Q34083191-FFF1F2BC-8A76-46CB-8739-FCBA999CAD51Q34100606-99782782-C5EA-42C8-94DC-DFF8533B2EBFQ36692818-78AC5B52-E7B4-4DDF-BA54-7D0846634A5CQ38196575-900DE6A3-7693-44FA-8A22-3F1E32DB5333Q38284227-C8342680-42D4-4637-BE39-4E80B0F6D6BFQ38920449-7701A799-A920-4BE8-A343-8737B3FFB768Q43015547-31D03FEF-51C4-4151-B6E0-7E83D21C9929Q45871404-88424D93-01D3-40F2-B7D2-DA98F33C7EB1Q48288188-31B59184-4CD1-4ED2-A54D-14AE267EA5CBQ50756733-D48A453D-8212-4F65-B54D-319E01477DFCQ52723748-BBB1F7EF-3B6B-4E13-B608-922BB8A1C555Q52947176-2CF6F272-4DF1-4DC3-A02F-B36701C2ABEDQ53580598-C5BBE01A-00FA-41AC-8EAF-B8C31E84F5FAQ54958100-997A3B31-2A16-4683-BE63-83D2D4C78EC5Q55069785-C2FF2EA7-306D-4D01-9D69-2FB3F3A53484Q57114299-F218C308-1CF4-4095-87AA-CBB082D171C2Q64983015-950E7EC5-8D4B-4792-AF40-3698B5E39B48Q83482480-319D366F-E647-412B-A919-BEC23F4FAD90Q83929177-ADF984AB-9246-49CA-83E7-2507E99E89A0Q84439641-A30A00E5-565C-481F-9615-8BDCD9289BBBQ87047792-4FA82DE4-C2BF-4DC3-9327-10FCEEE426FEQ87966122-BBE07CED-01BA-43D1-976C-47D3DF5429D7Q88142913-2530517F-6EB8-48C1-9975-6C3E646C6A00Q89549674-F8260AA6-5AAF-40A7-9490-67D19182E817Q89743470-989393E4-2E0F-4AF2-80D0-DD9DB083FA0AQ90142434-B976D32D-7CD2-49F5-B291-03504FDD7DCFQ90216523-72AAFD6C-3258-45D6-8EBC-DE5A5CB58B15Q91232457-F3C5020C-0090-42F8-87DB-91C287C7FBDEQ92133734-4E17606F-EFF4-4D39-8184-CC9B9E5B6F1DQ92284494-36BAACA3-8317-4BDC-8ABC-3A71D0FA84D6Q92609400-BDFEB7FD-1F71-46A3-A43E-58E6120F6DD5Q92692211-A21F2CAB-AB33-432D-9246-3DCC36879762Q96437663-8CB37AE7-BF91-4511-8556-E33C546238A4
P50
description
investigador
@es
researcher
@en
name
Elena Balestreire Hawryluk
@en
type
label
Elena Balestreire Hawryluk
@en
prefLabel
Elena Balestreire Hawryluk
@en
P31
P496
0000-0002-0862-3339